Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 81,961 shares, a decline of 63.9% from the August 15th total of 227,041 shares. Based on an average trading volume of 45,216 shares, the short-interest ratio is currently 1.8 days. Currently, 0.1% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IPHA. Jane Street Group LLC acquired a new position in Innate Pharma during the fourth quarter worth about $162,000. OLD Mission Capital LLC acquired a new stake in shares of Innate Pharma in the 4th quarter valued at approximately $50,000. Finally, Millennium Management LLC acquired a new stake in shares of Innate Pharma in the 4th quarter valued at approximately $36,000. Institutional investors own 0.16% of the company’s stock.

Innate Pharma Trading Down 0.5%

Shares of IPHA stock traded down $0.01 during trading hours on Friday, reaching $1.87. The company’s stock had a trading volume of 8,325 shares, compared to its average volume of 37,134. Innate Pharma has a fifty-two week low of $1.17 and a fifty-two week high of $2.71. The firm’s 50 day simple moving average is $1.97 and its 200-day simple moving average is $1.74.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on IPHA shares. HC Wainwright increased their target price on Innate Pharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Weiss Ratings raised Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 26th. Citigroup upgraded Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday, August 11th. BTIG Research boosted their target price on shares of Innate Pharma from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Finally, Leerink Partners upgraded shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price target on the stock in a research note on Tuesday, August 11th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Innate Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $6.67.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.